Insider · CIK 0001373097

JONES WILLIAM A JR

Reports to the SEC for 7 companies · SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001373097

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-03	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−7,657 sh	—	—	0
2026-09-03	APGEApogee Therapeutics, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−34.8K sh	—	—	0
2026-09-03	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.4K sh	—	—	0
2026-09-03	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−14.5K sh	—	—	0
2026-08-03	APMDApnimed, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	+44.5K sh	—	—	0
2026-08-03	APMDApnimed, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+44.5K sh	—	—	44,477
2026-07-30	APMDApnimed, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+44.5K sh	—	—	44,477
2026-06-11	ANNXAnnexon, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+65K sh	—	—	65,000
2026-06-09	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+7,657 sh	—	—	7,657
2025-06-17	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.5K sh	—	—	14,461
2025-06-05	ANNXAnnexon, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+55K sh	—	—	55,000
2025-01-09	ANNXAnnexon, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+88K sh	—	—	88,000
2025-01-07	NAMSNewAmsterdam Pharma Co N.V.A Award	Chief Commercial Officer	AAward	+43K sh	—	—	43,000
2025-01-02	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Chief Commercial Officer	AAward	+200K sh	—	—	200,000
2024-06-05	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10.4K sh	—	—	10,370
2023-05-02	Akili, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+22K sh	—	—	22,000
2022-11-02	Akili, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+44K sh	—	—	44,000
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardD Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−3,000 sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Stock Options (Right to Buy)D Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−775 sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Stock Options (Right to Buy)D Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−29.2K sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Stock Options (Right to Buy)D Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−2,398 sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Stock Options (Right to Buy)D Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−37.6K sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Stock Options (Right to Buy)D Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−1,742 sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Stock Options (Right to Buy)D Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−28.3K sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Stock Options (Right to Buy)D Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−5,913 sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Stock Options (Right to Buy)D Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−44.1K sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardD Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−11.3K sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardD Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−10K sh	—	—	0
2022-10-03	Biohaven Pharmaceutical Holding Co Ltd.D Disposition to Issuer	CCO-Migraine & Common Disease	DDisposition to Issuer	−14.2K sh	$148.50	−$2.11M	0
2022-01-07	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardM Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	−3,750 sh	—	—	11,250
2022-01-07	Biohaven Pharmaceutical Holding Co Ltd.M Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	+3,750 sh	—	—	15,630
2022-01-07	Biohaven Pharmaceutical Holding Co Ltd.F Tax Payment	CCO-Migraine & Common Disease	FTax Payment	−1,631 sh	$128.87	−$210K	13,999
2022-01-07	Biohaven Pharmaceutical Holding Co Ltd.Employee Stock Option (right to buy)A Award	CCO-Migraine & Common Disease	AAward	+30K sh	—	—	30,000
2022-01-07	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardA Award	CCO-Migraine & Common Disease	AAward	+15K sh	—	—	15,000
2022-01-06	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardM Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	−5,000 sh	—	—	10,000
2022-01-06	Biohaven Pharmaceutical Holding Co Ltd.F Tax Payment	CCO-Migraine & Common Disease	FTax Payment	−2,230 sh	$123.86	−$276K	11,880
2022-01-06	Biohaven Pharmaceutical Holding Co Ltd.M Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	+5,000 sh	—	—	14,110
2021-11-25	Biohaven Pharmaceutical Holding Co Ltd.M Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	+3,000 sh	—	—	10,127
2021-11-25	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardM Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	−3,000 sh	—	—	3,000
2021-11-25	Biohaven Pharmaceutical Holding Co Ltd.F Tax Payment	CCO-Migraine & Common Disease	FTax Payment	−1,305 sh	$115.55	−$151K	8,822
2021-01-06	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardM Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	−5,000 sh	—	—	15,000
2021-01-06	Biohaven Pharmaceutical Holding Co Ltd.M Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	+5,000 sh	—	—	9,251
2021-01-06	Biohaven Pharmaceutical Holding Co Ltd.F Tax Payment	CCO-Migraine & Common Disease	FTax Payment	−2,124 sh	$83.38	−$177K	7,127
2021-01-06	Biohaven Pharmaceutical Holding Co Ltd.Employee Stock Option (right to buy)A Award	CCO-Migraine & Common Disease	AAward	+40K sh	—	—	40,000
2021-01-06	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardA Award	CCO-Migraine & Common Disease	AAward	+20K sh	—	—	20,000
2020-11-25	Biohaven Pharmaceutical Holding Co Ltd.M Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	+3,000 sh	—	—	4,755
2020-11-25	Biohaven Pharmaceutical Holding Co Ltd.F Tax Payment	CCO-Migraine & Common Disease	FTax Payment	−1,245 sh	$90.14	−$112K	3,510
2020-11-25	Biohaven Pharmaceutical Holding Co Ltd.Restricted Share Unit AwardM Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	−3,000 sh	—	—	6,000
2020-11-02	Biohaven Pharmaceutical Holding Co Ltd.Employee Stock Option (Right to Buy)M Exercise/Conversion	CCO-Migraine & Common Disease	MExercise/Conversion	−30K sh	—	—	50,000
2020-11-02	Biohaven Pharmaceutical Holding Co Ltd.S Sale	CCO-Migraine & Common Disease	SSale	−1,300 sh	$77.70	−$101K	1,755

Recent filings

Accepted (ET)
Sep 34
JONES WILLIAM A JR0001140361-26-035614
SEC(opens sec.gov)
Aug 34
JONES WILLIAM A JR0001193125-26-330503
SEC(opens sec.gov)
Jun 154
JONES WILLIAM A JR0001373097-26-000001
SEC(opens sec.gov)
Jun 114
JONES WILLIAM A JR0001104659-26-073059
SEC(opens sec.gov)
Jun 204
JONES WILLIAM A JR0001104659-25-061275
SEC(opens sec.gov)
Jun 94
JONES WILLIAM A JR0001415889-25-016243
SEC(opens sec.gov)
Jan 104
JONES WILLIAM A JR0001415889-25-001308
SEC(opens sec.gov)
Jan 74
JONES WILLIAM A JR0000950170-25-002988
SEC(opens sec.gov)
Jan 64
JONES WILLIAM A JR0000950170-25-002363
SEC(opens sec.gov)
Jun 74
JONES WILLIAM A JR0001104659-24-069803
SEC(opens sec.gov)
May 44
JONES WILLIAM A JR0000899243-23-012262
SEC(opens sec.gov)
Nov 44
JONES WILLIAM A JR0000899243-22-035242
SEC(opens sec.gov)
Oct 34
JONES WILLIAM A JR0001562180-22-006962
SEC(opens sec.gov)

Companies

Address

C/O APOGEE THERAPEUTICS, INC. 1 LETTERMAN DRIVE, BUILDING B

SAN FRANCISCO, CA, 94129